For instance, the frequent co-occurrence of MYC amplifications with TP53 mutations in breast cancer might also lead to aberrant miRNA network activation81,82 and could partially explain the discrepancy between our findings from clinical specimens and previous results from cell models discussed above. This evidence concerns the gene TP53 and breast cancer.